Metsera, Inc.

Metsera, Inc.

MTSR·NASDAQ

$70.50

+0.0000%
HealthcareBiotechnology

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.

At a Glance

Live Snapshot
Market Cap$7.43B
EPS-2.0300
P/E Ratio-34.73
Earnings Date03/25/2026

mtsr

Total Debt

Last Annual Value

9.80M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Metsera, Inc.

Metsera, Inc. Competitors Analysis of Total Debt

MTSR · NASDAQ
CompanyTotal Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
MTSR logo
Metsera, Inc.
NASDAQ:MTSR
9.80M
N/AN/AN/A 
366.28M
-1.5%70.3%63.2%
ACLX logo
Arcellx, Inc.
NASDAQ:ACLX
96.26M
-0.5%N/AN/A
241.29M
9.0%37.2%37.8%
1.28B
19.3%36.6%46.9%
NUVL logo
Nuvalent, Inc.
NASDAQ:NUVL
0.00
N/AN/AN/A
246.47M
480.5%149.5%N/A
PCVX logo
Vaxcyte, Inc.
NASDAQ:PCVX
228.84M
98.6%68.6%N/A
Metsera, Inc.

Metsera, Inc. Fair Value Envelope

MTSR · NASDAQ

Our analysis suggests that MTSR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $70.5, this represents a potential HIDDEN relative to our calculated worth for Metsera, Inc..

Intrinsic Value
Current Price: $70.5